No Data
No Data
華領醫藥-B:年報 2023
Hualing Pharmaceutical (02552) announces 2023 results: R&D expenses of about 172 million yuan to actively promote the overseas market layout of second-generation GKA
On March 28, Hualing Pharmaceutical (02552) announced its 2023 results
HUA MEDICINE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Hualing Pharmaceutical-B (02552.HK) held a board meeting on March 28 to consider and approve the annual results
Gelonghui, March 18 | Hualing Pharmaceutical-B (02552.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve, including the Group's annual results for the year ended December 31, 2023, and the proposed final dividend (if any), and other matters.
HUA MEDICINE-B: Date of Board Meeting
Changes in Hong Kong stocks | Hualing Pharmaceutical-B (02552) rose more than 6%. Second-generation GKA submitted an IND application to the US FDA, Huatangning's sales volume can be expected
Hualing Pharmaceutical-B (02552) rose more than 6%. As of press release, it rose 6.19% to HK$2.4, with a turnover of HK$6.734,900.
No Data